New York, NY Clinical Trials Report — May 2026

For New Yorkers considering participation in clinical research, May 2026 presents both urgent opportunities and exciting new avenues for contributing to medical science. Across New York City, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 224 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 44 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers, infectious diseases, and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (7 trials)
• Cancer (5 trials)
• Prostate cancer (5 trials)
• Glioblastoma (4 trials)
• HIV infections (3 trials)
• Myelodysplastic syndromes (3 trials)
• Non-small cell lung cancer (3 trials)
• Head and neck cancer (3 trials)
• Alzheimer disease (3 trials)
• Glioblastoma multiforme (3 trials)

New Research Opportunities Emerge

This month, New York City saw the opening of 57 new clinical trials, an increase from the 51 trials that launched in April 2026. This brings the total number of actively recruiting clinical trials in New York, NY, to 3,125 across 1,301 research facilities, underscoring the city's robust research landscape.

May brings several high-profile new trials to New York, NY, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• NYU Langone Health is sponsoring NCT07607522, "Cardiac Rehab Referral Nudges," an observational study involving 7,000 participants. Investigators will evaluate the effectiveness of two different EHR-embedded nudges to improve referral to cardiac rehabilitation.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.
• The Physicians Committee for Responsible Medicine is sponsoring NCT07595562, "Acceptability of Soy Milk as a Calcium-Rich Beverage in School Children in New York City Public Schools." This study involves 2,500 participants and aims to understand student choices, milk waste reduction, and potential environmental and nutritional impacts of offering soy milk.
• Natural Cycles is behind NCT07566793, "Validation of Effectiveness on NaturalCycles Users," an observational study with 2,000 participants. It seeks to measure the effectiveness of the Natural Cycles digital birth control application in preventing pregnancy.
• The New York State Psychiatric Institute is sponsoring NCT07594730, "RCT of Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems." This study, with 1,600 participants, aims to test brief video interventions for parental internalized stigma and related outcomes among parents of children with depression, ADHD, or substance use problems.

New trials this month are exploring a range of conditions, with the most frequent being pancreatic cancer (3 trials), obesity (3 trials), major depressive disorder (2 trials), substance abuse (2 trials), and lymphoma (2 trials). Drug trials account for the largest share of new studies, with 26 new drug trials, followed by 13 device trials and 13 other types of studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 9 of the 57 new trials launched this month are actively seeking healthy volunteers. Across New York City, a total of 368 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

New York City's Leading Research Facilities

New York City is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Memorial Sloan Kettering Cancer Center (472 trials)
• NYU Langone Health (252 trials)
• Icahn School of Medicine at Mount Sinai (224 trials)
• Columbia University Irving Medical Center (160 trials)
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) (137 trials)
• Mount Sinai Hospital (120 trials)
• Columbia University Medical Center (118 trials)
• Weill Cornell Medicine (112 trials)
• Columbia University (98 trials)
• Research Site (78 trials)
• Laura and Isaac Perlmutter Cancer Center at NYU Langone (64 trials)
• Hospital for Special Surgery (60 trials)

These institutions offer a broad spectrum of research, from oncology at Memorial Sloan Kettering and NYU Langone's Perlmutter Cancer Center, to diverse medical fields at NYU Langone Health, Icahn School of Medicine at Mount Sinai, and Columbia University's medical centers.

Broadening Your Search: Nearby Options

While New York City offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within New York State. Cities with active trials include Rochester (8 trials), The Bronx (5 trials), Buffalo (5 trials), Brooklyn (4 trials), Staten Island (3 trials), Uniondale (3 trials), Harrison (3 trials), and Albany (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 57 new trials launched this month, 48 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 10 new trials include children, 5 are female-only, and 4 are male-only. Academic institutions continue to play a vital role in New York City's research ecosystem, with NYU Langone Health (9 trials), Columbia University (6 trials), and Icahn School of Medicine at Mount Sinai (5 trials) sponsoring the most new studies. Industry sponsors like AstraZeneca (4 trials) and Novo Nordisk A/S (3 trials) are also driving significant research efforts.

As we move further into spring, New York City's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.